Mingming Zhang, Guoqing Wei, Linghui Zhou, Jincai Zhou, Siye Chen, Wei Zhang, Dongrui Wang, Xueping Luo, Jiazhen Cui, Simao Huang, Shan Fu, Xinkai Zhou, Yu Tang, Xiaomin Ding, Jiao Kuang, Xiaowen Peter He, Yongxian Hu, He Huang
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has shown activity in treating relapsed or refractory multiple myeloma; however, relapse is still common, and new targets are needed. We aimed to assess the activity and safety profile of G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma. METHODS: POLARIS was a first-in-human, single-centre, single-arm, phase 1 trial of GPRC5D-targeted CAR T cells (OriCAR-017) done at the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China...
February 2023: Lancet Haematology